Atherosclerotic Cardiovascular Disease (ASCVD) is a progressive and long-term condition characterized by the accumulation of plaque in the arteries, leading to their narrowing. This disease impacts multiple arterial systems—including coronary arteries (heart), cerebral arteries (brain), and peripheral arteries (legs). The primary forms of ASCVD are coronary artery disease (CAD), cerebrovascular conditions like stroke, and peripheral arterial disease (PAD).
Risk factors such as poor nutrition, physical inactivity, tobacco use, alcohol consumption, obesity, and family history significantly increase the likelihood of developing ASCVD. While early stages may present no noticeable signs, progressive artery blockage often results in symptoms such as angina, dizziness, fatigue, heart palpitations, shortness of breath, and cold sweats.
📌 Dive into ASCVD prevalence and market visuals:
👉 Atherosclerotic Cardiovascular Disease Market Infographic
—
📈 ASCVD Epidemiology in the 7MM
Between 2020 and 2034, ASCVD epidemiology across the seven major markets (7MM)—the US, EU4 (Germany, France, Italy, Spain), the UK, and Japan—is segmented by:
-
Total diagnosed prevalence
-
Gender-specific prevalence
-
Age-specific prevalence
-
Comorbidity-based prevalence
In 2023, the total diagnosed population living with ASCVD in the 7MM reached nearly 55.7 million. The United States accounted for approximately 26 million cases, with continued growth projected. Germany led among European nations with 5 million cases, while France had 4 million and Spain recorded the lowest with 3 million. Japan reported about 8 million diagnosed cases, comprising 15% of the total 7MM burden.
Regarding comorbid conditions, “other coronary heart diseases (CHD)” were the most widespread, totaling 28 million cases in 2023. Other prevalent conditions included ischemic stroke, recent acute coronary syndrome (ACS), peripheral artery disease (PAD), and chronic kidney disease (CKD).
In the EU4 and the UK, male cases outnumbered female cases—12 million compared to 8 million in 2023.
📘 For full epidemiology and trends, access the complete report:
👉 ASCVD Market Forecast & Report
—
💰 ASCVD Market Outlook and Growth Trends
The ASCVD market in the 7MM was valued at approximately USD 23 billion in 2023, driven by rising prevalence, better diagnostics, and ongoing therapeutic advancements.
Key Market Growth Drivers:
-
Standardized treatment guidelines improve clinical decision-making and patient care.
-
A significant opportunity exists in developing therapies for lowering lipoprotein(a) [Lp(a)], which currently lacks FDA-approved treatments.
Challenges Impacting the Market:
-
Many patients fail to follow prescribed medications and recommended lifestyle changes, reducing treatment success.
-
Regulatory complexity can delay the approval of innovative drugs and devices.
📊 Explore dynamics shaping ASCVD treatment strategies:
👉 ASCVD Market Insights Infographic
—
🧪 Pipeline Developments and Leading Companies in ASCVD
The therapeutic landscape for ASCVD is evolving with new treatments designed to target currently unmet needs:
-
Olpasiran – An RNA interference therapy under development by Amgen to lower Lp(a) levels
-
Obicetrapib – A cholesterol-modifying CETP inhibitor developed by NewAmsterdam Pharma
-
Other emerging therapies focused on reducing cardiovascular risk and plaque buildup
Prominent players leading innovation in this space include:
-
Amgen Inc.
-
Merck Sharp & Dohme Corp.
-
NewAmsterdam Pharma
📚 Get full pipeline details and company profiles here:
👉 Atherosclerotic Cardiovascular Disease Market Report
